Related references
Note: Only part of the references are listed.Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary A Report of the AAN Guideline Subcommittee
Tamara Pringsheim et al.
NEUROLOGY (2021)
Parkinson's disease
Bastiaan R. Bloem et al.
LANCET (2021)
International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson's Disease
Susan H. Fox et al.
MOVEMENT DISORDERS (2018)
Longitudinal analysis of impulse control disorders in Parkinson disease
Jean-Christophe Corvol et al.
NEUROLOGY (2018)
Projections of Prevalence, Lifetime Risk, and Life Expectancy of Parkinson's Disease (2010-2030) in France
Mathilde Wanneveich et al.
MOVEMENT DISORDERS (2018)
Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
E. Ray Dorsey et al.
LANCET NEUROLOGY (2018)
The Emerging Evidence of the Parkinson Pandemic
E. Ray Dorsey et al.
JOURNAL OF PARKINSONS DISEASE (2018)
A Randomized Trial of a Low-Dose Rasagiline and Pramipexole Combination (P2B001) in Early Parkinson's Disease
C. Warren Olanow et al.
MOVEMENT DISORDERS (2017)
Global, Regional, and National Levels of Maternal Mortality, 1990–2015
OBSTETRICAL & GYNECOLOGICAL SURVEY (2017)
Combination therapy in combating cancer
Reza Bayat Mokhtari et al.
ONCOTARGET (2017)
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial
Thomas M. MacDonald et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
The Prevalence of Parkinson's Disease: A Systematic Review and Meta-analysis
Tamara Pringsheim et al.
MOVEMENT DISORDERS (2014)
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
Anthony H. V. Schapira et al.
LANCET NEUROLOGY (2013)
Twice-Daily, Low-Dose Pramipexole in Early Parkinson's Disease: A Randomized, Placebo-Controlled Trial
Karl Kieburtz
MOVEMENT DISORDERS (2011)
Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline
Peter Jenner et al.
MOVEMENT DISORDERS (2011)
Extended-release pramipexole in early Parkinson disease A 33-week randomized controlled trial
W. Poewe et al.
NEUROLOGY (2011)
Extended-release pramipexole in advanced Parkinson disease A randomized controlled trial
A. H. V. Schapira et al.
NEUROLOGY (2011)
Update on the use of pramipexole in the treatment of Parkinson’s disease
Radu Constantinescu
Neuropsychiatric Disease and Treatment (2011)
The Clinically Important Difference on the Unified Parkinson's Disease Rating Scale
Lisa M. Shulman et al.
ARCHIVES OF NEUROLOGY (2010)
Long-Term Efficacy of Rasagiline in Early Parkinson's Disease
Mark F. Lew et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2010)
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline
Orit Bar-Am et al.
JOURNAL OF NEUROCHEMISTRY (2010)
Randomized, Double-Blind, Multicenter Evaluation of Pramipexole Extended Release Once Daily in Early Parkinson's Disease
Robert A. Hauser et al.
MOVEMENT DISORDERS (2010)
Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole
Stefan Albrecht et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
C. Warren Olanow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro
Orit Bar-Am et al.
JOURNAL OF NEUROCHEMISTRY (2007)
1-Aminoindan, a main metabolite of rasagiline, enhances dopamine release and provides symptomatic benefit in an animal model of Parkinson's disease
J. Brotchie et al.
PARKINSONISM & RELATED DISORDERS (2007)
Relating mode of action to clinical practice: Dopaminergic agents in Parkinson's disease
Peter Riederer et al.
PARKINSONISM & RELATED DISORDERS (2007)
Drug insight: new drugs in development for Parkinson's disease
Carlo Colosimo et al.
NATURE CLINICAL PRACTICE NEUROLOGY (2006)
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
Trond Kvernmo et al.
CLINICAL THERAPEUTICS (2006)
Association of dopamine agonist use with impulse control disorders in Parkinson disease
Daniel Weintraub et al.
ARCHIVES OF NEUROLOGY (2006)
Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease
C. Warren Olanow
NEUROLOGY (2006)
Suboptimal medication adherence in Parkinson's disease
KA Grosset et al.
MOVEMENT DISORDERS (2005)
Sudden uncontrollable somnolence and medication use in Parkinson disease
J Avorn et al.
ARCHIVES OF NEUROLOGY (2005)
Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition
MBH Youdim et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2005)
Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline:: A potent, selective, and irreversible monoamine oxidase type B inhibitor
JJ Thébault et al.
PHARMACOTHERAPY (2004)
Dopamine agonists and neuroprotection in Parkinson's diseae
AHV Schapira
EUROPEAN JOURNAL OF NEUROLOGY (2002)
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor.: II.: Agonist and antagonist properties at subtypes of dopamine D2-like receptor and α1/α2-adrenoceptor
A Newman-Tancredi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B
MBH Youdim et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
O Rascol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
